Objective: To investigate the clinical value of combined detection of serum miR-378 and miR-21 in gastric cancer (GC). Methods: Eighty-seven patients with GC and 78 patients with colorectal cancer(CRC) from National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences were selected, 83 individuals undergoing healthy physical examination were selected as the healthy controls. The levels of serum miR-378 and miR-21 were detected by quantitative real-time PCR (RT-qPCR) (result data were transformed as log2 for analysis). Results: Relative expression levels of miR-378 in the serum were -1.24, -3.25 and -2.73 in healthy controls, GC and CRC patients, respectively. Compared with the healthy controls, the levels of serum miR-378 were significantly decreased in GC and CRC patients (both P<0.05). Relative expression levels of miR-21 in the serum were 0.11, 2.34 and 2.47 in healthy controls, GC and CRC patients, respectively. Compared with the healthy controls, the levels of serum miR-21 were significantly up-regulated in GC and CRC patients (both P<0.05). Moreover, the serum level of miR-378 in GC patients was inversely associated with tumor clinical stage (P<0.05). However, the level of miR-21 showed no significant differences among patients with different clinical and pathological characteristics (all P>0.05). The area under the receiver operating characteristic curve (AUC), sensitivity and specificity of miRNA-378 to diagnose GC was 0.770, 82.0% and 66.0%, respectively, and were 0.900, 85.0%, and 88.0% of miR-21, respectively. The AUC, sensitivity and specificity of combined detection of serum miR-378 and miR-21 to diagnose GC were 0.930, 92.0% and 87.0%, respectively, while the AUC of combined detection of serum CEA and CA-199 was 0.767, the AUC of combined all of the four factors was 0.946. Conclusion: The combined detection of serum miR-378 and miR-21 have a certain effect on diagnosis of GC.
目的： 探讨血清miR-378和miR-21联合检测对胃癌的临床诊断价值。 方法： 选择中国医学科学院肿瘤医院经病理确诊的胃癌患者87例，结直肠癌患者78例，健康体检者83例，采用实时荧光定量PCR法检测血清样本中miR-378和miR-21的表达水平(以log(2)对结果进行转换)。 结果： miR-378在健康对照者、胃癌患者和结直肠癌患者血清中的相对表达水平分别为－1.24、－3.25和－2.73，miR-378在胃癌和结直肠癌患者血清中的相对表达水平明显低于健康对照者(均P<0.05)。miR-21在健康对照者、胃癌患者和结直肠癌患者血清中的相对表达水平分别为0.11、2.34和2.47，miR-21在胃癌和结直肠癌患者血清中的相对表达水平明显高于健康对照者(均P<0.05)。胃癌患者血清中miR-378的低表达与肿瘤的临床分期有关(P<0.05)，分期越晚，下降程度越大；而miR-21在胃癌患者血清中的升高程度与患者的临床病理特征无关(均P>0.05)。血清miR-378诊断胃癌的曲线下面积(AUC)为0.770，灵敏度为82.0%，特异度为66.0%；miR-21诊断胃癌的AUC为0.900，灵敏度为85.0%，特异度为88.0%；miR-378＋miR-21诊断胃癌的AUC为0.930，灵敏度为92.0%，特异度为87.0%。CEA＋CA-199诊断胃癌的AUC为0.767，CEA＋CA-199＋miR-378＋miR-21诊断胃癌的AUC为0.946。 结论： 联合检测血清中miR-378和miR-21的表达对胃癌具有一定的诊断效能。.
Keywords: Diagnose; Gastric neoplasms; Serum; miR-21; miR-378.